Filing Flows › Sunshine Biopharma (SBFM) › Q1 2026 › vs Q1 2025
Sunshine Biopharma (SBFM) Q1 2026 vs Q1 2025 (year over year)
Sunshine Biopharma's revenue fell $813K (-9%) from $8.9M in Q1 2025 to $8.1M in Q1 2026.
Sunshine Biopharma, Q1 2026: revenue $8.1M (-9% year over year), operating margin -17.3%, net loss $1.2M, operating cash flow −$2.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $8.1M | $8.9M | −$813K | -9% |
| Other income, net | $152K | $76K | $76K | +100% |
| Net loss | $1.2M | $1.2M | $64K | +5% |
| Costs & expenses | $9.5M | $10.2M | −$713K | -7% |
| Operating costs | $9.5M | $10.2M | −$713K | -7% |
| Cost of revenue | $5.9M | $6.2M | −$263K | -4% |
| Operating expenses | $3.6M | $4.0M | −$450K | -11% |
| Operating cash sources | $2.1M | $1.8M | $389K | +22% |
| Depreciation & amortization | $77K | $65K | $12K | +19% |
| Cash used in operations | $2.1M | $1.7M | $377K | +22% |
| Net loss absorbed | $1.2M | $1.2M | $64K | +5% |
| Working capital & other | $905K | $580K | $325K | +56% |
Questions
How much did Sunshine Biopharma's revenue grow year over year in Q1 2026?
Sunshine Biopharma's revenue fell $813K (-9%) from $8.9M in Q1 2025 to $8.1M in Q1 2026.